Thursday, April 23, 2020 8:46:43 PM
I believe there are a number of hospitals here in the U.S. participating in clinical trials utilizing the drug. Diverting one or more doses to use in coronavirus shouldn't be a problem.
The biggest problem with compassionate use, or right to try, is that it's possible to be paid, but only if you're willing to provide a great deal of information on the cost of making the drug. Most companies won't do that to be paid the cost of making it, so they either don't participate, or give it away. Many don't participate in the program because of that. I believe they ought to price the products at some percentage of SOC treatment, I think far more companies would be willing to participate if that were the case.
Gary
ZenaTech, Inc. (NASDAQ: ZENA) Launchs IQ Nano Drone for Commercial Indoor Use • HALO • Oct 10, 2024 8:09 AM
CBD Life Sciences Inc. (CBDL) Targets Alibaba as the Next Retail Giant for Wholesale Expansion of Top-Selling CBD Products • CBDL • Oct 10, 2024 8:00 AM
Foremost Lithium Announces Option Agreement with Denison on 10 Uranium Projects Spanning over 330,000 Acres in the Athabasca Basin, Saskatchewan • FAT • Oct 10, 2024 5:51 AM
Element79 Gold Corp. Reports Significant Progress in Community Relations and Development Efforts in Chachas, Peru • ELEM • Oct 9, 2024 10:30 AM
Unitronix Corp Launches Share Buyback Initiative • UTRX • Oct 9, 2024 9:10 AM
BASANITE INDUSTRIES, LLC RECEIVES U.S. PATENT FOR ITS BASAFLEX™ BASALT FIBER COMPOSITE REBAR AND METHOD OF MANUFACTURING • BASA • Oct 9, 2024 7:30 AM